CytomX Therapeutics reported Q2 2026 financial results showing a revenue decline to $1.4 million from $18.7 million in the prior year period, driven by the completion of performance obligations with Bristol Myers Squibb and lower Astellas collaboration activity. Operating expenses increased to $25.2 million due to Varseta-M manufacturing and personnel costs, resulting in a net loss of $20.7 million compared to a $154,000 loss previously. The company ended the quarter with $330.3 million in cash and investments. Pipeline updates include planned FDA interactions for Varseta-M's registrational study in colorectal cancer, expected by late 2026, with initiation targeted for early 2027. Additionally, CytomX received a $37.0 million target selection payment from Regeneron in July 2026 and appointed new board member Dr. Charles Fuchs along with executive leadership additions. The company operates as a clinical-stage biopharmaceutical firm developing conditionally activated biologics for oncology.

CytomX Therapeutics, Inc. announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective July 24, 2026. Dr. Fuchs will receive standard non-employee director compensation and an option to purchase 118,000 shares of common stock under the 2015 Equity Incentive Plan. CytomX Therapeutics, Inc. is a biotechnology company focused on developing clinical-stage therapeutics.

On June 17, 2026, stockholders approved increasing the authorized common stock from 300,000,000 to 600,000,000 shares, with the Certificate of Amendment filed on June 22, 2026. Stockholders also approved increasing the 2015 Equity Incentive Plan by 6,500,000 shares and the Employee Stock Purchase Plan by 1,000,000 shares. Other meeting outcomes included the election of Class II directors Matthew P. Young and Elaine V. Jones, ratification of Ernst & Young LLP as auditor, and approval of executive compensation on an advisory basis. CytomX Therapeutics, Inc. is a biotechnology company that develops therapeutic antibodies.